HARPOON THERAPEUTICS TO PARTICIPATE IN THREE UPCOMING INVESTOR CONFERENCES

On September 1, 2022 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, reported that management will participate in three upcoming investor conferences (Press release, Harpoon Therapeutics, SEP 1, 2022, View Source [SID1234618904]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conduct one-on-one investor meetings at Citi’s 17th Annual BioPharma Conference on Thursday, September 8, 2022;

A corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference, at 11:30 a.m. ET on Monday, September 12, 2022; and

A corporate presentation and fireside chat at Baird’s 2022 Global Healthcare Conference, at 4:20 p.m. ET on Tuesday, September 13, 2022.
Presentations will be available in the Investors section of the Harpoon Therapeutics website at www.harpoontx.com with an archived replay available following the event.

Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences

On September 1, 2022 Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) reported that it is scheduled to participate in the following upcoming events (Press release, Arrowhead Pharmaceuticals, SEP 1, 2022, View Source [SID1234618903]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

European Respiratory Society (ERS) International Congress 2022 – September 4-6, 2022

Title: Silencing MMP7 expression with a lung-targeted RNAi molecule limits fibrosis and preserves pulmonary function in bleomycin-injured rats
Presenter: Erik Bush, Ph.D., Group Vice President, Biology, Arrowhead Pharmaceuticals

2022 Wells Fargo Healthcare Conference – September 7-9, 2022

Type: Investor meetings
Presenter: Vincent Anzalone, CFA, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals

H.C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022

Type: Fireside chat presentation
Presenter: Christopher Anzalone, Ph.D., President and CEO, Arrowhead Pharmaceuticals

Baird 2022 Global Healthcare Conference – September 13-14, 2022

Type: Fireside chat presentation
Presenter: Christopher Anzalone, Ph.D., President and CEO, Arrowhead Pharmaceuticals

Morgan Stanley 20th Annual Global Healthcare Conference – September 12-14, 2022

Type: Fireside chat presentation
Presenter: Christopher Anzalone, Ph.D., President and CEO, Arrowhead Pharmaceuticals

A copy of the presentation materials and webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

On September 1, 2022 KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, reported that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation at the H.C. Wainwright 24th Annual Global Investment Conference being held from September 12-14, 2022, in New York, New York (Press release, KemPharm, SEP 1, 2022, View Source [SID1234618902]). In addition, management will be available for virtual one-on-one investor meetings during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Registered investors will be able to view the pre-recorded presentation by Dr. Mickle highlighting KemPharm’s business and recent corporate achievements, as well as anticipated milestones. The presentation can be viewed on-demand starting at 7:00 a.m. ET on September 12, 2022, and will be available under the "Events & Presentations" within the Investor Relations section of KemPharm’s website at View Source

AFFIMED TO PRESENT AT UPCOMING INVESTOR CONFERENCES

On September 1, 2022 Affimed N.V. (Nasdaq: AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that the Company’s management will participate in the following investor conferences during the month of September 2022 (Press release, Affimed, SEP 1, 2022, View Source [SID1234618901]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2022 Wells Fargo Healthcare Conference (September 6-9, 2022)
Date: Wednesday, September 7, 2022
Presentation Time: 3:10 p.m. Eastern Daylight Time
Webcast: View Source
Location: Boston, MA

Citi’s 17th Annual BioPharma Virtual Conference (September 6-8, 2022)
Date: Thursday, September 8, 2022
Only one-on-one meetings
Location: Boston, MA

Morgan Stanley’s 20th Annual Global Healthcare Conference (September 12-14, 2022)
Date: Tuesday, September 13, 2022
Only one-on-one meetings
Location: New York, NY

Jefferies Cell and Genetic Medicine Summit (September 29-30, 2022)
Date: Thursday, September 29, 2022
Only one-on-one meetings
Location: New York, NY

For more information or to schedule a one-on-one meeting with Affimed’s management, please contact your event representative or Alex Fudukidis via email at [email protected] or phone at +1 (917) 436-8102.

MEDIGENE PARTICIPATES AT UPCOMING SCIENTIFIC CONFERENCES

On September 1, 2022 Medigene AG ( View Source) (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer therapies, reported that it will participate at the following upcoming scientific conferences (Press release, MediGene, SEP 1, 2022, View Source [SID1234618900]). Medigene’s management and/or scientists will be available for one-on-one meetings at these events.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

7th CAR-TCR Summit
19-22 September 2022
Boston, MA, USA
https://car-tcr-summit.com/

Immuno UK
29-30 September 2022
London, United Kingdom
View Source

10th Annual Immuno-Oncology Summit
12-14 October 2022
Boston, MA, USA
https://www.immuno-oncologysummit.com/

Cell UK
7-8 November 2022
London, United Kingdom
View Source